BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16361574)

  • 1. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.
    Li Y; Idamakanti N; Arroyo T; Thorne S; Reid T; Nichols S; VanRoey M; Colbern G; Nguyen N; Tam O; Working P; Yu DC
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8845-55. PubMed ID: 16361574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.
    Ryan PC; Jakubczak JL; Stewart DA; Hawkins LK; Cheng C; Clarke LM; Ganesh S; Hay C; Huang Y; Kaloss M; Marinov A; Phipps SS; Reddy PS; Shirley PS; Skripchenko Y; Xu L; Yang J; Forry-Schaudies S; Hallenbeck PL
    Cancer Gene Ther; 2004 Aug; 11(8):555-69. PubMed ID: 15232601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
    Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
    Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication.
    Kamizono J; Nagano S; Murofushi Y; Komiya S; Fujiwara H; Matsuishi T; Kosai K
    Cancer Res; 2005 Jun; 65(12):5284-91. PubMed ID: 15958575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase-dependent oncolytic adenovirus for cancer treatment.
    Huang TG; Savontaus MJ; Shinozaki K; Sauter BV; Woo SL
    Gene Ther; 2003 Aug; 10(15):1241-7. PubMed ID: 12858189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent.
    Zou W; Luo C; Zhang Z; Liu J; Gu J; Pei Z; Qian C; Liu X
    Oncogene; 2004 Jan; 23(2):457-64. PubMed ID: 14724574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy.
    Su C; Na M; Chen J; Wang X; Liu Y; Wang W; Zhang Q; Li L; Long J; Liu X; Wu M; Fan X; Qian Q
    Mol Cancer Res; 2008 Apr; 6(4):568-75. PubMed ID: 18344493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
    Zhu M; Bristol JA; Xie Y; Mina M; Ji H; Forry-Schaudies S; Ennist DL
    J Virol; 2005 May; 79(9):5455-65. PubMed ID: 15827160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.
    Dilley J; Reddy S; Ko D; Nguyen N; Rojas G; Working P; Yu DC
    Cancer Gene Ther; 2005 Aug; 12(8):715-22. PubMed ID: 15832172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis.
    Lanson NA; Friedlander PL; Schwarzenberger P; Kolls JK; Wang G
    Cancer Res; 2003 Nov; 63(22):7936-41. PubMed ID: 14633724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers.
    Gu J; Kagawa S; Takakura M; Kyo S; Inoue M; Roth JA; Fang B
    Cancer Res; 2000 Oct; 60(19):5359-64. PubMed ID: 11034071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell.
    Tsukuda K; Wiewrodt R; Molnar-Kimber K; Jovanovic VP; Amin KM
    Cancer Res; 2002 Jun; 62(12):3438-47. PubMed ID: 12067986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.